HC Wainwright restated their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report released on Monday morning,Benzinga reports. Get Viking Therapeutics alerts:Read Our Latest Research Report on Viking TherapeuticsViking Therapeutics Stock Up 0.9%Shares of NASDAQ VKTX opened at $25.81 on Monday. Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. Viking Therapeutics Company Profile(Get Free Report)Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Further ReadingReceive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.